Current Oncology,
Год журнала:
2024,
Номер
31(8), С. 4753 - 4761
Опубликована: Авг. 20, 2024
Improvements
in
downstaging
therapies
have
expanded
the
indications
for
liver
transplantation
(LT)
hepatocellular
carcinoma
(HCC).
Patients
with
more
advanced
disease
are
now
considered
candidates
due
to
advancements
radiation
therapy,
combination
therapies,
and
immunotherapy.
Combination
stereotactic
body
therapy
(SBRT)
trans-arterial
chemoembolization
(TACE)
has
been
shown
be
superior
historic
treatment,
sorafenib,
patients
macrovascular
invasion.
These
LT
stable
after
LRT.
ruptured
HCC
prolonged
stability
also
acceptable
outcomes.
The
role
of
neoadjuvant
immunotherapy
needs
further
defined
potential
improve
tumor
control
prior
transplant.
Journal of Hepatocellular Carcinoma,
Год журнала:
2024,
Номер
Volume 11, С. 1389 - 1402
Опубликована: Июль 1, 2024
The
dominant
artery
blood
supply
is
a
characteristic
of
hepatocellular
carcinoma
(HCC).
However,
it
not
known
whether
the
can
predict
post-hepatectomy
prognosis
patients
with
HCC.
This
retrospective
study
investigated
prognostic
value
portal
venous
and
arterial
estimated
on
triphasic
liver
CT
(as
coefficient,
PVC,
hepatic
HAC,
respectively)
in
HCC
following
hepatectomy.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(17), С. 13274 - 13274
Опубликована: Авг. 26, 2023
Hepatocellular
carcinoma
(HCC)
is
one
of
the
most
common
solid
tumor
malignancies
in
world
and
represents
roughly
90%
all
primary
liver.
The
risk
factors
for
HCC
include
hepatitis
B
virus,
C
alcohol,
increasingly,
fatty
Most
diagnosed
at
advanced
stages,
excluding
possibility
curative
resection,
which
leaves
systemic
therapy
as
only
treatment
option.
However,
given
extreme
mutational
diversity
heterogenous
nature
HCC,
efforts
to
develop
new
targeted
therapies
were
largely
unsuccessful
until
recently.
pathogenesis
thought
be
a
multistage
process
driven
by
wide
array
nonmutually
exclusive
driver
mutations
accompanied
many
passenger
mutations,
with
average
possessing
approximately
40
genomic
aberrations.
Over
past
two
decades,
several
categorize
prognostically
therapeutically
according
different
molecular
subclassifications
intent
guide
identify
drug
targets
have
emerged,
though,
no
single
consensus
has
been
reached.
Recent
breakthroughs
development
greatly
expanded
options,
but
ideal
uniting
each
patient's
unique
remains
elusive.
Frontiers in Pharmacology,
Год журнала:
2024,
Номер
15
Опубликована: Фев. 1, 2024
Hepatocellular
carcinoma
(HCC)
is
one
of
the
most
prevalent
cancers
worldwide
and
accounts
for
more
than
90%
primary
liver
cancer.
The
advent
immune
checkpoint
inhibitor
(ICI)-related
therapies
combined
with
angiogenesis
inhibition
has
revolutionized
treatment
HCC
in
late-stage
unresectable
HCC,
as
ICIs
alone
were
disappointing
treating
HCC.
In
addition
to
altered
microenvironment,
abnormal
lipid
metabolism
been
extensively
characterized
various
types
Stains
are
known
their
cholesterol-lowering
properties
long
history
hypercholesterolemia
reducing
cardiovascular
disease
risk.
Apart
from
ICI
other
conventional
therapies,
statins
frequently
used
by
advanced
patients
dyslipidemia,
which
often
marked
accumulation
cholesterol
fatty
acids
liver.
Supported
a
body
preclinical
clinical
studies,
may
unexpectedly
enhance
efficacy
therapy
through
regulation
inflammatory
responses
microenvironment.
This
review
discusses
changes
summarizes
evidence
benefits
stain
use
prospects
possible
mechanistic
actions
transforming
microenvironment
when
immunotherapies.
Consequently,
statin
emerge
novel
valuable
adjuvant
immunotherapies
Biomedicine & Pharmacotherapy,
Год журнала:
2024,
Номер
177, С. 116839 - 116839
Опубликована: Июнь 17, 2024
Dual-specificity
tyrosine
phosphorylation-regulated
kinase
2
(DYRK2)
and
histone
deacetylase
8
(HDAC8)
have
been
shown
to
be
associated
with
the
development
of
several
cancers.
Here,
we
identified
a
dual-target
DYRK2/HDAC8
inhibitor
(DYC-1)
through
combined
virtual
screening
protocol.
DYC-1
exhibited
nanomolar
inhibitory
activity
against
both
DYRK2
(IC50
=
5.27
±
0.13
nM)
HDAC8
8.06
0.47
nM).
Molecular
dynamics
simulations
showed
that
had
positive
binding
stability
HDAC8.
Importantly,
cytotoxicity
assay
indicated
superior
antiproliferative
human
liver
cancer,
especially
SK-HEP-1
cells,
no
significant
inhibition
on
normal
cells.
Moreover,
strong
effect
growth
xenograft
tumors
side
effects.
These
data
suggest
is
high-efficacy
low-toxic
antitumor
agent
for
treatment
hepatocellular
carcinoma.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(13), С. 6830 - 6830
Опубликована: Июнь 21, 2024
Hepatocellular
carcinoma
(HCC)
is
the
sixth
most
prevalent
cancer
and
a
significant
global
health
burden,
with
increasing
incidence
rates
limited
treatment
options.
Immunotherapy
has
become
promising
approach
due
to
its
ability
affect
immune
microenvironment
promote
antitumor
responses.
The
performs
an
essential
role
in
both
progression
development
of
HCC,
different
characteristics
based
on
specific
cells
etiological
factors.
Immune
checkpoint
inhibitors,
including
programmed
death-1/programmed
death-ligand
1
inhibitors
(pembrolizumab,
nivolumab,
durvalumab)
cytotoxic
T
lymphocyte
antigen-4
(tremelimumab
ipilimumab),
have
potential
treat
advanced
HCC
overcome
adverse
effects,
such
as
liver
failure
chemoresistance.
Phase
II
phase
III
clinical
trials
highlight
efficacy
pembrolizumab
respectively,
patients,
demonstrated
by
their
positive
effects
overall
survival
progression-free
survival.
Tremelimumab
exhibited
modest
response
rates,
though
it
does
possess
antiviral
activity.
Thus,
still
being
investigated
ongoing
trials.
Combination
therapies
multiple
drugs
benefits
terms
tumor
improving
patient
outcomes
compared
monotherapy,
especially
for
advanced-stage
HCC.
This
review
addresses
immunotherapies
early-,
intermediate-,
Additionally,
highlights
how
combination
therapy
can
significantly
enhance
survival,
objective
rate
where
options
are
limited.
Journal of Chemotherapy,
Год журнала:
2023,
Номер
36(4), С. 299 - 318
Опубликована: Окт. 25, 2023
This
study
aimed
to
optimize
nanosuspension
of
sorafenib
tosylate
(an
anticancer
hydrophobic
drug
molecule)
using
a
central
composite
design.
Nanosuspension
was
prepared
nanoprecipitation-ultrasonication
approach.
FTIR
and
DSC
analyses
demonstrated
that
the
excipients
were
physicochemically
compatible.
X-ray
powder
diffraction
analysis
confirmed
amorphous
form
payload
in
formulation.
The
optimized
formulation
(batch
NSS6)
had
zeta
potential
−18.1
mV,
polydispersity
0.302,
particle
size
97.11
nm.
SEM
formation
rod-shaped
particles.
After
24
h,
about
64.45%
86.37%
released
pH
6.8
1.2,
respectively.
MTT
assay
performed
on
HepG2
cell
lines.
IC50
value
batch
39.4
µg/mL.
concluded
could
be
promising
approach
treatment
hepatocellular
cancer.
Experimental and Therapeutic Medicine,
Год журнала:
2023,
Номер
27(1)
Опубликована: Ноя. 22, 2023
The
reprogramming
of
lipid
metabolism
serves
an
important
role
in
occurrence
and
development
liver
cancer.
Fatty
acid
hydroxylase
domain
containing
2
(FAXDC2)
is
a
involved
the
synthesis
cholesterol
sphingomyelin
downregulated
various
types
There
are
no
reports
on
relationship
between
FAXDC2
carcinogenesis.
present
study
used
multiple
portals
publicly
available
tools
to
explore
its
correlation
with
results
showed
that
expression
decreased
cancer
methylation
level
near
promoter
increased.
Patients
low
had
poor
prognosis.
Gain
function
loss
strategies
were
performed
evaluate
roles
cells.
CCK‑8
assay
overexpression
inhibited
viability
cells
(HepG2).
Flow
cytometry
analysis
indicated
HepG2
overexpressing
S
phase
arrest,
associated
cyclin‑dependent
kinase
decreased.
Transwell
experiments
increasing
cell
invasion
ability,
accompanied
by
upregulation
E‑cadherin.
Notably,
knockdown
significant
effect
cycle
functions.
Based
cBioPortal
platform,
was
predicted
closely
correlate
ERK
signal
tumorigenesis.
Western
blotting
phosphorylation
first
identified
as
suppressor,
which
might
inhibit
proliferation
through
mechanism
signaling.
provided
possible
new
target
for
diagnosis
treatment
2017 IEEE International Ultrasonics Symposium (IUS),
Год журнала:
2023,
Номер
unknown, С. 1 - 4
Опубликована: Сен. 3, 2023
Minimally
invasive
thermal
ablation
of
liver
tumors,
including
microwave
and
RF
ablation,
would
benefit
from
improved
intraprocedural
monitoring
to
assess
treatment
progress.
Echo
decorrelation
imaging
has
been
proposed
quantify
rapid
echo
signal
changes
caused
by
tissue
heating.
Previous
studies
have
shown
that
is
a
better
predictor
effects
than
in
echogenicity.
Here,
the
feasibility
percutaneous
hepatocellular
carcinoma
(HCC)
using
was
tested
clinical
study.
Consenting
subjects
were
recruited
patients
scheduled
for
standard-of-care
HCC
ablation.
Subjects
underwent
radiofrequency
guided
B-mode
ultrasound
(US)
with
frequency
2.2
MHz.
Throughout
each
procedure,
groups
20
sequential
beamformed
frames
acquired
at
30
s
intervals.
Acquired
used
compute
US,
decorrelation,
integrated
backscattered
(IBS)
images.
US
images
coregistered
follow-up
triphasic
CT
Receiver
operating
characteristic
(ROC)
curves
calculated
prediction
local
thresholded
IBS
maps.
Area
under
ROC
showed
predicted
RFA
significantly
HCC.
Although
further
study
needed,
these
results
suggest
an
effective
approach
